



Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.



MET Exon 14 Deletion Analysis

Alternative Name

MET Exon 14 Skipping

Methodology

Molecular

Test Description

MET Exon 14 Deletion Analysis is performed by real-time RT-PCR. The assay is designed to detect alternative splice junctions that lead to exon-skipping (deletion) of exon 14 of the gene MET. Note: Available as stand-alone test or as part of the NeoTYPE® Lung Tumor Profile.

Clinical Significance

The MET (mesenchymal-epithelial transition) tyrosine kinase receptor and its ligand the hepatocyte growth factor (HGF) play a major role in oncogenesis in various types of cancers. MET amplification and mutations have been reported in various types of tumors, especially lung cancer. MET amplification or mutation can be primary or acquired after treatment with EGFR kinase inhibitors. The expression of a defective MET mRNA that skips exon 14 is recently reported in 4% of lung cancers. This finding is very important, because it is actionable. Dramatic response to MET/ALK inhibitors (crizotinib and cabozantinib) can be seen in patients with lung cancer and METex14 abnormality. Testing for METex14 is now considered by multiple clinical investigators as a standard of care in patients with lung cancer. MET exon 14 deletion is also seen in a subset of gastric and gastrointestinal carcinomas and gliomas.

Specimen Requirements

- **FFPE solid tumor tissue:** Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.

Storage & Transportation

Use cold pack for transporting block during summer to prevent block from melting. Slides can be packed at room temperature.

CPT Code(s)*

81479

New York Approved

No

Level of Service

Global

Turnaround Time

14 days

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way
Fort Myers, FL 33912
Phone: 239.768.0600/ Fax: 239.690.4237
neogenomics.com
© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved.
All other trademarks are the property of their respective owners
Rev. 070324